Trial Profile
A Phase I Study of MK-4827 in Patients With Advanced Solid Tumors or Hematologic Malignancies.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Niraparib (Primary)
- Indications Advanced breast cancer; Chronic lymphocytic leukaemia; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Solid tumours; T-cell prolymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 04 Jun 2013 Status changed from active, no longer recruiting to completed, according to results reported in Tesaro media release.
- 04 Jun 2013 Results presented at ASCO 2013, according to Tesaro media release.
- 15 Apr 2013 Planned End Date changed from 1 Dec 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.